MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares of its common stock pursuant to its […]
Other News
Last patient included in Acarix’s exploratory heart failure study SEISMO
Malmö, Sweden May 11, 2020 Last patient included in Acarix’s exploratory heart failure study SEISMO Acarix AB (publ) today announced that the last patient has been included in the exploratory SEISMO study on a potential heart failure application. The exploratory clinical heart failure trial SEISMO was initiated in June 2018 to evaluate the possibility […]
ZOLL Announces Return of Department of Health and Human Services Funds Distribution
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei Group company that manufactures medical devices and related software solutions, announced the return of funds it received from the Department of Health and Human Services (HHS) as part of the CARES Act Provider Relief Fund. The CARES Act Provider Relief Fund allocated […]
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
Fast Track Designation Highlights the Urgent Need for New Heart Failure Treatment Options THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin […]
CryoLife Initiates Enrollment in PROACT Xa Clinical Trial
Study Designed to Evaluate the Use of Apixaban in On-X Aortic Valve Patients ATLANTA, May 7, 2020 /PRNewswire/ — CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has initiated enrollment in the PROACT Xa clinical trial, a prospective, randomized, trial to determine if […]
FARAPULSE’s Pioneering Clinical Results Link Compelling Long-term Outcomes to Established Safety and Lesion Durability Data
MENLO PARK, CA, May 7, 2020 /PRNewswire/ – FARAPULSE Inc. (“FARAPULSE” or “the Company”) and its pulsed field ablation (PFA) technology for Atrial Fibrillation featured heavily in the collection of science published online by the Heart Rhythm Society in lieu of an annual meeting. Highlights of the data presented by the investigators from seven […]
PINNACLE FLX Study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device Presented as Late-Breaking Clinical Trial at HRS 2020 SCIENCE
Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillation MARLBOROUGH, Mass., May 8, 2020 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive 12-month results from the PINNACLE FLX clinical trial assessing the safety and efficacy […]
Neovasc Announces First Quarter Financial Results
Promotes John Panton to Chief Quality Officer VANCOUVER and MINNEAPOLIS, MN, May 07, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported […]
Michael Schmertzler Joins the Board of ViralClear Pharmaceuticals, a Majority-Owned Subsidiary of BioSig Technologies, Inc.
Pharmaceutical expert and Chairman of PTC Therapeutics joins other biotech leaders as Independent Director Westport, CT, May 07, 2020 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) today appointed Mr. Michael Schmertzler to the Board of Directors of its majority-owned subsidiary ViralClear Pharmaceuticals, Inc. Mr. Schmertzler […]
iRhythm Technologies Announces First Quarter 2020 Financial Results
SAN FRANCISCO, May 07, 2020 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended March 31, 2020. First Quarter 2020 Highlights Revenue of $63.5 million for the three […]



